Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): A cluster-randomised trial

The Lancet Infectious Diseases

Volumn 12, Issue 4, 2012, Pages 300-306

  Pereira, Susan M ^a   Barreto, Mauricio L ^a   Pilger, Daniel ^b   Cruz, Alvaro A ^a   Sant'Anna, Clemax ^c   Hijjar, Miguel A ^d   Ichihara, Maria Y ^a   Santos, Andreia C ^b   Genser, Bernd ^a,e   Rodrigues, Laura C ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADOLESCENT; ARTICLE; AXILLARY LYMPHADENITIS; BCG VACCINATION; BRAZIL; CHILD; CLUSTER ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; INFECTION RATE; LYMPHADENITIS; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; TUBERCULIN TEST; TUBERCULOSIS; ULCER;

ADOLESCENT; BCG VACCINE; CHILD; CLUSTER ANALYSIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VACCINATION;

EID: 84859003138     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70285-7     Document Type: Article

References (35)

1. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163:1009-1021.
2. WHO Position Paper on BCG vaccination. Wkly Epidemiol Rec 2004, 79:25-40.
3. Rodrigues LC, Diwan VK, Wheeler JG Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993, 22:1154-1158.
4. Fine P, Carneiro A, Milstien J, Clements C Issues relating to the use of BCG in immunization programmes 1999, WHO, Geneva.
5. WHO. Tuberculosis: fact sheet No 104. 2010 (accessed March 30, 2011).
6. Bakshi D, Sharief N Selective neonatal BCG vaccination. Acta Paediatr 2004, 93:1207-1209.
7. Clark A, Sanderson C Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009, 373:1543-1549.
8. Trunz BB, Fine P, Dye C Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367:1173-1180.
9. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996, 348:17-24. Karonga Prevention Trial Group.
10. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res 1999, 110:56-69. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention.
11. Clemens J, Brenner R, Rao M, Tafari N, Lowe C Evaluating new vaccines for developing countries. Efficacy or effectiveness?. JAMA 1996, 275:390-397.
12. Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366:1290-1295.
13. Barreto ML, Rodrigues LC, Cunha SS, et al. Design of the Brazilian BCG-REVAC trial against tuberculosis: a large, simple randomized community trial to evaluate the impact on tuberculosis of BCG revaccination at school age. Control Clin Trials 2002, 23:540-553.
14. Pereira SM, Bierrenbach AL, Dourado I, et al. [Sensitivity and specificity of the BCG scar reading]. Rev Saude Publica 2003, 37:254-259. (in Portuguese).
15. Pereira SM, Dourado I, Barreto ML, et al. Sensitivity and specificity of BCG scar reading in Brazil. Int J Tuberc Lung Dis 2001, 5:1067-1070.
16. Barreto ML, Pereira SM, Pilger D, et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011, 29:4875-4877.
17. Camargos PA, Guimaraes MD, Antunes CM Risk assessment for acquiring meningitis tuberculosis among children not vaccinated with BCG: a case-control study. Int J Epidemiol 1988, 17:193-197.
18. Wunsch Filho V, de Castilho EA, Rodrigues LC, Huttly SR Effectiveness of BCG vaccination against tuberculous meningitis: a case-control study in Sao Paulo, Brazil. Bull World Health Organ 1990, 68:69-74.
19. Dourado I, Rios MH, Pereira SM, et al. Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Int J Tuberc Lung Dis 2003, 7:399-402.
20. Costa JG, Santos AC, Rodrigues LC, Barreto ML, Roberts JA [Tuberculosis in Salvador, Brazil: costs to health system and families]. Rev Saude Publica 2005, 39:122-128.
21. Programa Nacional De Controle Da Tuberculose (PNCT) Ministerio da Saude, (accessed March 29, 2011). http://portal.saude.gov.br/portal/saude/profissional/visualizar_texto.cfm?idtxt=31101.
22. Penna G, Pinto LF, Soranz D, Glatt R High incidence of diseases endemic to the Amazon region of Brazil, 2001-2006. Emerg Infect Dis 2009, 15:626-632.
23. Brito RC, Mello FC, Andrade MK, et al. Drug-resistant tuberculosis in six hospitals in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2010, 14:24-33.
24. Marques M, Cunha EA, Ruffino-Netto A, Andrade SM [Drug resistance profile of Mycobacterium tuberculosis in the state of Mato Grosso do Sul, Brazil, 2000-2006]. J Bras Pneumol 2010, 36:224-231.
25. Matos ED, Lemos AC, Bittencourt C, Mesquita CL Anti-tuberculosis drug resistance in strains of Mycobacterium tuberculosis isolated from patients in a tertiary hospital in Bahia. Braz J Infect Dis 2007, 11:331-338.
26. Santos LC, Bousquet Hde M, Pereira AM, Junqueira-Kipnis AP, Kipnis A A high prevalence of resistance in new tuberculosis cases of midwestern Brazil. Infect Genet Evol 2010, 10:1052-1057.
27. Liang KY, Zeger SL Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
28. Bierrenbach AL, Cunha SS, Barreto ML, et al. Tuberculin reactivity in a population of schoolchildren with high BCG vaccination coverage. Rev Panam Salud Publica 2003, 13:285-293.
29. Rede Interagencial de Informações para a Saúde-RIPSA. Indicadores e Dados Básicos-Brasil, 2008-IDB Ministério da Saúde, (accessed Nov 2, 2011). http://tabnet.datasus.gov.br/cgi/idb2008/matriz.htm#recur.
30. Fine PE, Ponnighaus JM, Maine N The distribution and implications of BCG scars in northern Malawi. Bull World Health Organ 1989, 67:35-42.
31. Barreto ML, Cunha SS, Pereira SM, et al. Neonatal BCG protection against tuberculosis lasts for 20 years in Brazil. Int J Tuberc Lung Dis 2005, 9:1171-1173.
32. Johannesson M, Meltzer D Some reflections on cost-effectiveness analysis. Health Econ 1998, 7:1-7.
33. Meltzer D, Johannesson M Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making 1999, 19:371-377.
34. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
35. Springett VH, Sutherland I BCG vaccination of schoolchildren in England and Wales. Thorax 1990, 45:83-88.